Skipping surgery after rectal cancer treatment pays off long-term. A post-hoc analysis published in JAMA Network Open found that locally advanced rectal cancer patients who achieved complete clinical response after total neoadjuvant therapy and chose watch-and-wait had significantly better quality of life than those who underwent surgery — with improvements in bowel function, physical ability, and social well-being lasting up to 5 years.
For patients with locally advanced rectal cancer who achieve a complete clinical response after total neoadjuvant therapy, skipping surgery may be the better long-term choice. A post-hoc analysis of two prospective phase 2 trials, published in JAMA Network Open, found that the watch-and-wait approach delivered statistically significant and clinically meaningful quality of life (QOL) benefits over total mesorectal excision (TME) — the standard surgical option — across a wide range of functional domains over 5 years of follow-up.
The study drew on data from 385 patients treated across 19 German centers between 2015 and 2020. Of these, 56 were assigned to watch-and-wait after achieving complete clinical response, while 329 underwent immediate TME. Even among patients who remained disease-free throughout follow-up, watch-and-wait still came out ahead.
Key Takeaways:
Why it matters: In the absence of randomized controlled trials, this analysis offers meaningful evidence that organ preservation after complete clinical response is not just oncologically viable — it significantly improves patients' day-to-day lives. These findings could reshape shared decision-making conversations between clinicians and rectal cancer patients.
